Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trachisan is a combination throat lozenge indicated for the symptomatic relief of inflammatory and infectious conditions of the oral cavity and pharynx, such as sore throat, pharyngitis, and gingivitis. The formulation contains three active components: **tyrothricin**, a topical antibiotic that disrupts bacterial membranes; **chlorhexidine digluconate**, a broad-spectrum antiseptic; and **lidocaine hydrochloride**, a local anesthetic that provides rapid pain relief by blocking voltage-gated sodium channels. Originally developed by Engelhard Arzneimittel and marketed by FarmaSyn in the Greek market, Trachisan is an over-the-counter (OTC) product designed for local application in the mouth and throat.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Trachisan.